CJC-1295 vs MK-677 (Ibutamoren)
Overview
CJC-1295 and MK-677 (Ibutamoren) are both performance & growth peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares CJC-1295 and MK-677 (Ibutamoren) across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| CJC-1295 | MK-677 (Ibutamoren) | |
|---|---|---|
| Category | Performance & Growth | Performance & Growth |
| Regulatory status (US) | Research use only | Research use only |
| Typical dosage | 1-2 mg | 10-25 mg |
| Frequency | weekly | daily |
| Reported benefits | Increased muscle mass, fat loss, improved recovery, better sleep, enhanced bone density | Increased appetite, muscle growth, improved sleep, bone density enhancement |
| Reported side effects | Water retention, joint pain, potential insulin resistance with prolonged use | Increased appetite, water retention, elevated blood sugar, potential insulin resistance |
Key differences
Primary use. CJC-1295 is categorised under Performance & Growth, while MK-677 (Ibutamoren) falls under Performance & Growth. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. CJC-1295: not FDA-approved; treated as a research compound. MK-677 (Ibutamoren): not FDA-approved; treated as a research compound.
Dosing. CJC-1295 is typically dosed at 1-2 mg (weekly). MK-677 (Ibutamoren) is typically dosed at 10-25 mg (daily).
Can you stack them?
Some protocols combine peptides, but stacking CJC-1295 and MK-677 (Ibutamoren) has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between CJC-1295 and MK-677 (Ibutamoren)?
- CJC-1295 and MK-677 (Ibutamoren) are both performance & growth peptides, but they differ in mechanism, dosing, and regulatory status. CJC-1295 is not FDA-approved; generally classified as a research compound, whereas MK-677 (Ibutamoren) is not FDA-approved; generally classified as a research compound.
- What is CJC-1295 used for?
- Growth hormone, muscle mass, fat loss.
- What is MK-677 (Ibutamoren) used for?
- Oral GH secretagogue.
- Can you take CJC-1295 and MK-677 (Ibutamoren) together?
- Some users combine peptides within a single protocol, but stacking CJC-1295 and MK-677 (Ibutamoren) has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is CJC-1295 or MK-677 (Ibutamoren) FDA-approved?
- CJC-1295 is not FDA-approved; generally classified as a research compound. MK-677 (Ibutamoren) is not FDA-approved; generally classified as a research compound.
Read the full articles
- CJC-1295 — full monograph: mechanism, research, dosing & references
- MK-677 (Ibutamoren) — full monograph: mechanism, research, dosing & references